Non-Alcoholic Fatty Liver Disease as an Emerging Risk Factor for Heart Failure

被引：0
作者：
Riccardo M. Inciardi
Alessandro Mantovani
Giovanni Targher
机构：
[1] University of Brescia,ASST Spedali Civili Di Brescia, Division of Cardiology and Department of Medical and Surgical Specialties, Radiological Sciences and Public Health
[2] University of Verona,Department of Medicine, Section of Endocrinology, Diabetes, and Metabolism
来源：
Current Heart Failure Reports | 2023年 / 20卷
关键词：
NAFLD; Non-alcoholic fatty liver disease; Heart failure; Metabolic dysfunction-associated fatty liver disease; Cardiovascular disease;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：308 / 319
页数：11
相关论文
共 377 条
  • [71] Fairweather D(2007)Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis Hepatology 9 4003-undefined
  • [72] Win S(2019)Connectivity mapping of angiotensin-PPAR interactions involved in the amelioration of non-alcoholic steatohepatitis by Telmisartan Sci Rep 54 1631-undefined
  • [73] Than TA(2011)Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial Hepatology 12 e0175717-undefined
  • [74] Younossi ZM(2017)A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis PLoS One. 22 1662-undefined
  • [75] Corey KE(2020)Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fraction Eur J Heart Fail undefined undefined-undefined
  • [76] Alkhouri N(undefined)undefined undefined undefined undefined-undefined
  • [77] Noureddin M(undefined)undefined undefined undefined undefined-undefined
  • [78] Jacobson I(undefined)undefined undefined undefined undefined-undefined
  • [79] Lam B(undefined)undefined undefined undefined undefined-undefined
  • [80] Riazi K(undefined)undefined undefined undefined undefined-undefined
3456789101112